MIT 001
Alternative Names: MIT-001Latest Information Update: 28 Jun 2025
At a glance
- Originator MitoImmune Therapeutics
- Class Anti-inflammatories; Antiasthmatics; Antifibrotics
- Mechanism of Action Antioxidants; Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Stomatitis
- Preclinical COVID 2019 infections
- No development reported Asthma; Graft-versus-host disease; Idiopathic pulmonary fibrosis; Unspecified
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in South Korea (SC, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Asthma in South Korea (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Graft-versus-host-disease in South Korea (IV, Infusion)